Probiotic

    Soil-Based Probiotics

    Bacillus coagulans, B. subtilis, B. clausii and related spore-formers

    TL;DR

    Soil-based (spore-forming) probiotics survive stomach acid far better than standard lactobacilli. Small trials support benefits for IBS-type symptoms and gut barrier integrity, but long-term safety data are limited.

    Ideal For

    • People with IBS-type bloating who have not responded to standard probiotics

    Avoid If

    • Severe immunocompromise
    • Critical illness or central lines

    Frequently Asked Questions

    Overview

    Soil-based probiotics contain spore-forming Bacillus species (B. coagulans, B. subtilis, B. clausii, B. indicus) that remain dormant through stomach acid and germinate in the small intestine. This solves the main weakness of conventional probiotics — poor survival. Human RCTs show modest benefits: B. coagulans reduced bloating and abdominal pain in IBS and functional dyspepsia trials, and a B. subtilis-based multi-strain product reduced markers of gut permeability (post-prandial endotoxemia) in healthy adults. Concerns include theoretical translocation risk in immunocompromised patients and variable strain identification in commercial products.

    How It Works

    • Spore coat survives gastric acid — high delivery efficiency
    • Produces bacteriocins and competitive exclusion of pathogens
    • May reduce metabolic endotoxemia by improving barrier function

    Quick Facts

    • Survive stomach acid and shelf-stable without refrigeration
    • Best-studied: B. coagulans for IBS symptoms
    • Not equivalent to traditional fermented-food probiotics

    Benefits & Outcomes

    No linked outcomes yet. Research is ongoing.

    Health Concerns Addressed

    IBS (Irritable Bowel Syndrome)

    condition
    Mixed evidence
    Moderate Evidence
    Effectiveness 3/5

    Small positive RCTs for B. coagulans in IBS, but short duration and industry funding keep the verdict at mixed.

    Supporting Research
    6 studies

    Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults

    Score: 7/10
    2019
    rct
    n=153

    Madempudi RS, Ahire JJ, Neelamraju J +2 more

    Spore-based B. coagulans improved IBS symptoms in adults over 8 weeks.

    View source

    The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial

    Score: 6/10
    2022
    rct
    n=76

    Garvey SM, Mah E, Blonquist TM +2 more

    BS50 increased the proportion of participants showing improvement from baseline to week 6 in the composite score for bloating, burping, and flatulence (47.4% vs. 22.2%)

    View source

    Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study

    Score: 5/10
    2016
    rct
    n=36

    Majeed M, Nagabhushanam K, Natarajan S +5 more

    Spore-forming B. coagulans was effective and well tolerated in IBS-D over 90 days.

    View source

    Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis

    Score: 8/10
    2018
    meta_analysis

    McFarland LV, Evans CT, Goldstein EJC

    Probiotic claims must be evaluated per strain rather than per species or category.

    View source

    Bacillus spp. spore-based probiotic supplementation and gut microbiota modulation in healthy adults

    Score: 5/10
    2019
    rct
    n=60

    Catinean A, Neag AM, Nita A +2 more

    Bacillus spore probiotics can modulate the gut microbiome of healthy adults.

    View source

    Efficacy of a synbiotic containing Bacillus coagulans in the treatment of irritable bowel syndrome: a randomized placebo-controlled trial

    Score: 5/10
    2014
    rct
    n=85

    Rogha M, Esfahani MZ, Zargarzadeh AH

    A B. coagulans synbiotic reduced key IBS symptoms in this trial.

    View source

    Safety Information

    Potential Side Effects

    Mild gas or bloating initially. Theoretical infection risk in severely immunocompromised patients.

    Contraindications

    Severe immunocompromise, central venous catheters, critical illness.

    Pregnancy & Breastfeeding

    Pregnancy: insufficient_data

    Breastfeeding: insufficient_data

    Dosage Guidelines

    Dosage Used in Studies

    1-5 billion CFU

    Best Form

    Bacillus coagulans (for digestive symptoms)

    Bioavailability

    High gastric survival due to spore coat; transient colonization rather than permanent engraftment.

    Forms Compared

    Most human trial data for IBS and bloating

    Marketed for gut barrier and immune support; less strain-specific evidence

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.